Abstract
Drug resistance often results in failure of anticancer chemotherapy in leukemias. A large number of studies have been published on the effect of P-glycoprotein (Pgp) expression on prognosis in AML. However, a consensus has been difficult to reach, due to the variable results obtained by different laboratories. Pgp expression was investigated here in bone marrow samples from 34 patients with AML including 19 newly diagnosed cases and 15 relapsing patients. Pgp expression was performed by immunocytochemistry (ICC) using the aviding-biotin-peroxydase technique with JSB1 and UIC2 MoAbs. Flow cytometry (FCM) analysis of Pgp expression was performed using UCI2 MoAbs in an indirect immunofluorescent assay without cell permeabilization. Rhodamine 123 (Rh 123) uptake was measured in the presence or absence of verapamil. Result was discordant in only 1/20 samples studied with both JSB1 and UIC2 by ICC. Results of Pgp expression were consistent on FCM and ICC in 23 of the 28 (82%) samples tested. Overall, Pgp expression was observed by ICC or FCM in 23 (67%) patients, including 11 (58%) newly diagnosed patients and 12 (80%) patients in relapse. Functional Rh123 efflux (Rh123+) was observed in 20 cases (59%): 10 de novo AML (53%) vs 10 AML in relapse (67%). The functional efflux was correlated with Pgp expression in 25 of the 34 cases analyzed (p=0.013). 3 (9%) and 6 (18%) samples were Pgp-/Rh123+ and Pgp+/Rh123- respectively. Nine of the 14 pts (64%) treated with intensive anthracyclin-Ara C chemotherapy achieved complete remission, including 5/5 (100%) Pgp- cases vs 4/9 (44%) Pgp+ cases (p=0.04) and 4/6 (67%) Rh 123- vs 4/7 (57%) Rh123+ cases (p=0.5). In conclusion, assessment of Pgp expression by ICC and FMC using 2 different MoAbs coupled with functional efflux analysis confirms that Pgp expression is correlated with disease stage and response to treatment in AML. Discordant Pgp/Rh123 cases suggest a non functional Pgp or another alteration of drug transport.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem., 1993, 62, 385–427.
Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchai S., Witz F., Rose C., Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glyprotein expression simultaneously detemined by flow cytometry. Blood, 1995, 85, 2147–2153.
Nüssler V., Pelka-Fleischer R., Zwierzina H., Nerl C., Beckert B., Gieseler F., Diem H., Ledderose G., Gullis E., Sauer H., Wilmanns W. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia, 1996, 10, 523–531.
Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., Head D.R., Appelbaum F.R, Willman C.L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standart chemotherapy: A Southwest Oncology Group study. Blood, 1997, 9, 3323–3329.
Mechetner E.B., Roninson I. Efficient inhibition of glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad., Sc. USA, 1992, 89, 5824–5828.
Miwa H., Kita K., Nishii K., Morita N., Takahura N., Ohishi K., Mahmud N., Kageyama S., Fukumoto M., Shirakawa S. Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood, 1993, 82, 3445–3451.
Lehne G., de Angelis P., Clausen O.P.F., Egeland T., Tsuruo T., Rugstad H.E. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry, 1995, 20, 228–237.
Marie J.P., Huet A.M, Faussat A.M., Perrot J.Y., Chevillard S., Barbu V., Bayle C., Boutorrat J., Calvo F., campos-Guyotat L., Colosetti P., Cazin J.L., Cremoux P., Delvincourt C., Demur C., Drenou B., Fenneteau O., Feuillard J., Garnier-Suillerot A., Genne P., Gorisse M.C., Gosselin P., Jouault H., Lacave R., Le Calvez G., Leglise M.C., Leonce S., Manfait M., Maynadie M., Merle-Beral H., Merlin J.L., Mousseau M., Morjani H., Pio F., Pinguet F., Poncelet P., Racadot E., Raphael M., Richard B., Rossi J.F., Schlegel N., Viehl P., Zhou D.C., Robert J. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia, 1997, 11, 1086–1094.
Beck W.T., Grognan T.M., Willman C.L., Cordon-Cardo, Parham D.M., Kuttesch J.F., Andreeff M., Bates S.E., Berard C.W., Boyett J.M., Brophy N.A., Broxtermann J.H., Chan H.L.S., Dalton W.S., Dietel M., Fojo A.T., Gascoyne R.D., Head D., Houghton P.J., Srivastava D.K., Lehnert M., Leith C.L., Paietta E., Pavelic Z.P., Rimsza L., Roninson I.B., Sikic B.I., Twentyman P.R., Warnke R., Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: consensus recommendations. Cancer Res., 1996, 56, 3010–3020.
Lepelley P., Soenen V., Preudhomme C., Lai J.L., Cosson A., Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 1994, 8, 998–1004.
Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gaattringer C., Huber H., Hoffman J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br. J. Haematol., 1992, 82, 161–168.
te Boekhorst P.A.W., de Leeuw K., Shoester M., Wittebol S., Nooter K., Hagemeijer A., Löwenberg B., Sonneveld P. Preominance of functional Multidrug Resistance (MDR1) phenotype in CD34+ acute myeloid leukemia cells. Blood, 1993, 82, 3157–3162.
Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., Weick J.K., Willman C.L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: indentification of discordant MDR1/Efflux+ and MDR1+/Efflux-cases. Blood,1995, 86, 2329–2342.
Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K., Stewart A., Kurz E., Duncan A., Deeley R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258, 1650–1654.
Cole S.P.C., Defley R.G. Multidrug resistance associated with overexpression of MRP Cancer Treat. Res., 1996, 87, 39–62.
Hart S.M., Ganesshagru K., Hoffbrand A.V., Prentice H.G., Mehta A.B. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia, 1994, 8, 2163–2168.
Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 1994, 83, 2451–2458.
Bailly D., Muller C., Jaffrezou J.P., Demur C., Cassar G., Bordier C., Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia, 1995, 9, 799–807.
Cumber P.M., Jacobs A., Hoy T., Whittaker J.A., Tsuruo T., Padua R.A. Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein. Leukemia, 1991, 5, 1050–1053.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Poulain, S., Lepelley, P., Cambier, N., Cosson, A., Fenaux, P., Wattel, E. (1999). Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow Cytometry Using Two Different Monoclonal Antibodies Coupled with Functional Efflux Analysis in 34 Patients with Acute Myeloid Leukemia. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive